外周动脉疾病患者接受 deceased donor 肾移植的生存获益
基于 SRTR 2003–2022 年 506,785 例成人肾移植等待者数据,8.7% 合并 PAD、36.0% 接受 DDKT。中位随访 3.21 年后,无论 PAD 状态,DDKT 较继续等待均显著降低死亡风险(校正 HR 0.45–0.60,P<0.001),PAD 不应视为 DDKT 绝对禁忌。
要点
- 合并 PAD 的肾移植等待者接受 DDKT 较继续等待死亡风险显著降低(校正 HR 0.45–0.60,P<0.001)。
- 按性别、种族和糖尿病状态分层后,DDKT 的生存获益未见实质性改变。
- PAD 不应作为 deceased donor 肾移植的绝对禁忌证。
核心结论
- 在 SRTR 数据库中将 PAD 二分类后,合并与不合并 PAD 的等待者接受 DDKT 较继续等待均获得相似的长期生存获益。
- PAD 不应成为 deceased donor 肾移植的绝对禁忌证。
研究设计与样本
- 共 506,785 例成人肾移植等待者,8.7% 合并 PAD,36.0% 接受 DDKT。
- 采用 Kaplan-Meier 生存估计和多变量 Cox 比例风险模型,按 PAD 状态分层比较接受 DDKT 与继续等待者的死亡风险。
主要发现
- 中位随访 3.21 年(IQR 1.11–7.03 年),死亡率随 DDKT 和 PAD 状态显著不同。
- 校正基线差异后,无论 PAD 状态,DDKT 较继续等待均与显著更低的死亡风险相关(校正 HR 0.45–0.60,P<0.001)。
- 按性别、种族和民族、糖尿病状态进一步分层未实质性改变上述结果。
关键数值与推荐
- DDKT 较继续等待的校正死亡风险比范围为 0.45–0.60,P<0.001,适用于合并与不合并 PAD 的等待者。
临床怎么用
- 对于合并 PAD 的 deceased donor 肾移植等待者,不应仅因 PAD 诊断而排除移植。
- 移植决策时应结合 PAD 的具体疾病谱和严重程度进行个体化评估。
局限性
- SRTR 数据库将 PAD 二分类捕捉,可能未充分反映 PAD 疾病谱的异质性。
- 研究为回顾性观察性设计,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peripheral artery disease (PAD) is a common comorbidity among patients waitlisted for deceased donor kidney transplant (DDKT). However, some centers consider PAD a contraindication for transplant given the higher risk of postoperative complications. We aimed to examine the survival benefit of DDKT among patients with and without PAD. METHODS: We used data from the Scientific Registry of Transplant Recipients (SRTR) from January 2003 to December 2022 to identify all DDKT waitlist candidates. Kaplan-Meier survival estimates and multivariable Cox proportional hazards models were used to compare patient mortality for those who received a DDKT versus those remaining on the waitlist, stratified by PAD status. RESULTS: Overall, 506,785 candidates were listed for adult kidney-only transplant during the study period, of which 8.7% had PAD and 36.0% received a DDKT. After a median follow-up time of 3.21 years from waitlist activation [interquartile range 1.11-7.03 years], mortality varied significantly according to DDKT and PAD status. After adjusting for baseline differences, DDKT was associated with a significantly lower hazard of death compared to remaining on the waitlist, regardless of PAD status [adjusted hazards ratio 0.45-0.60, P < 0.001]. Further stratifying by sex, race and ethnicity, and diabetes status did not substantially alter these results. CONCLUSION: PAD includes a spectrum of diseases with varying mortality risks. As captured and dichotomized in the SRTR database, DDKT conferred a similar long-term benefit relative to remaining on the waitlist for candidates with and without PAD. Therefore, PAD should not be an absolute contraindication to DDKT.
引用
- Tan LT, Kernodle AB, Yu S, et al. Survival Benefit of Deceased Donor Kidney Transplantation among Patients with Peripheral Artery Disease. Ann Vasc Surg. 2025. PMID: 40645573. doi:10.1016/j.avsg.2025.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。